Depomed (DEPO) shares were up 8% after hours after it reported quarterly results that surpassed the Street view and guided ahead of expectations.
The pharmaceutical company reported net income for Q4 2013 was $0.72 per share, compared to a net loss of $0.07 per share for Q4 2012. Q4 2013 revenue of $40.6 million, up from $26.6 million a year prior.
The Street expected revenue of $20 million and a loss of $0.20 per share, according to Capital IQ’s consensus.
For 2014, the company expects non-GAAP earnings of breakeven to $0.16 per share and revenue of approximately $200 million to $215 million. The Street calls for a loss of $0.28 per share on revenue of $26.9 million for 2014.
Suggested Reading: Best Job Markets In the World
